Recruiting

UI-EWD vs. Conventional

Sponsor:

Medtronic - MITG

Code:

NCT06188585

Conditions

Acute Gastrointestinal Bleeding

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

UI-EWD

Conventional therapy

Study Details

Brief summary:

A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.

Conditions

Acute Gastrointestinal Bleeding

Study ID

NCT06188585

Start date

Jun 21, 2024

Status verified date

Jun, 2026

Completion date

Sep, 2029

Anticipated

Primary completion date

Aug, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adults age 22 years or older
2. Presentation with acute overt gastrointestinal bleeding (hematemesis, melena, and/or hematochezia)
3. Subject voluntarily agrees to participate in the clinical investigation, provides written informed consent, and will be able to comply with the investigational protocol in the opinion of the site investigator
4. Cause of bleeding as determined at upper endoscopy is one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear. The definition of "active oozing" will require bleeding to persist for ≥ 3 minutes of endoscopic observation.

Exclusion Criteria:

1. Incarceration
2. Subjects that are not able to provide written informed consent
3. Pregnancy or nursing mothers
4. Endoscopic hemostatic treatment in the past 30 days
5. Use of triple antithrombotic therapy at the time of presentation
6. Subjects who underwent gastric or duodenal endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) procedures within the past 2 months
7. Post-polypectomy bleeding
8. Subjects with erosive esophagitis, erosive gastritis, esophageal ulcer, or vascular ectasia including gastric antral vascular ectasia
9. Platelet count < 50 x 10\^9/L
10. INR > 3.5 (or prothrombin time >35 seconds in patient not on warfarin and only prothrombin time is provided by local lab), at time of procedure or closest to procedure time
11. Subjects who have documented galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
12. Subjects with documented hypersensitivity to Brilliant Blue FCF
13. Subjects with suspected bowel obstruction or gastrointestinal fistulas, and those suspected or are at high risk of having gastrointestinal perforation.
14. Endoscopy not performed within 36 hours of presentation to hospital/emergency department

Study Design

Enrollment

278 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Test Group

UI-EWD

active comparator: Control Group

Conventional endoscopic therapy

Interventions

UI-EWD

Hemostatic powder administered at index endoscopy

Conventional therapy

Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy

Primary outcome measure

  • No further bleeding during the 7-day period after hemostatic treatment [ Time Frame: 7 days ]

Central Contacts and Locations

Locations

Yale

Recruiting

New Haven, Connecticut, United States, 06520

Principal Investigator:

Kenneth Hung, M.D.

RUSH University

Recruiting

Chicago, Illinois, United States, 60612

Principal Investigator:

Neal Mehta, M.D.

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Principal Investigator:

Linda Lee, MD

Rutgers University

Recruiting

Piscataway, New Jersey, United States, 08901

Principal Investigator:

Arvind Trindade, M.D.

Northwell Health

Recruiting

Manhasset, New York, United States, 11030

Principal Investigator:

Juan Bucobo, M.D.

NYU Langone

Recruiting

New York, New York, United States, 10016

Principal Investigator:

Melissa Debordeaux, M.D.

McGill University

Recruiting

Montreal, Quebec, Canada

Principal Investigator:

Yen-I Chen, M.D.

St. Michael's Hospital

Recruiting

Toronto, Canada

Principal Investigator:

Jeffrey Mosko, MD, MSc, FRCPC

Vancouver General Hospital

Recruiting

Vancouver, Canada

Principal Investigator:

Roberto Trasolini, MD

More Information

Sponsor

Medtronic - MITG

Last update posted

Jun 22, 2026

Last verified

Jun, 2026

Keywords

  • Gastrointestinal hemorrhage
  • Peptic Ulcer
  • Nonvariceal upper gastrointestinal bleeding

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Medtronic - MITG on 2026-06-22.